Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
20.85
-0.10 (-0.48%)
Mar 6, 2026, 1:43 PM EST - Market open
Immunome Employees
Immunome had 118 employees as of December 31, 2024. The number of employees increased by 63 or 114.55% compared to the previous year.
Employees
118
Change (1Y)
63
Growth (1Y)
114.55%
Revenue / Employee
$41,315
Profits / Employee
-$1,264,250
Market Cap
2.36B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 619 |
| Galapagos NV | 558 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Ocular Therapeutix | 325 |
| Wave Life Sciences | 317 |
IMNM News
- 21 hours ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 11 days ago - Immunome to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 2 months ago - Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 2 months ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire
- 2 months ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire